Outpatient worsening heart failure in transthyretin amyloid cardiomyopathy: Findings from ATTRibute-CM.
Detecting subtle worsening in heart failure through routine diuretic increases identifies high-risk patients who benefit from early preventive treatment in this rare cardiomyopathy.
Post-hoc analysis of the ATTRibute-CM RCT (n=611) reveals that outpatient worsening heart failure — marked simply by loop diuretic escalation — is a highly prognostic event in ATTR-CM and is significantly reduced by acoramidis treatment, with the benefit emerging within the first month. This provides a practical, easily monitored clinical endpoint and supports early initiation of acoramidis to prevent the cascade from subclinical worsening to hospitalization and death in this rare but increasingly diagnosed cardiomyopathy.
What the study was
- Study design
- Post-hoc exploratory analysis of phase 3 RCT (ATTRibute-CM, NCT03860935)
- Population
- Patients with transthyretin amyloid cardiomyopathy (ATTR-CM) enrolled in ATTRibute-CM phase 3 RCT
- Sample size
- 611
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- European Journal of Heart Failure
Why it surfaced
Post-hoc of a phase 3 RCT establishing outpatient HF worsening as a prognostic marker and acoramidis as reducing it by 41% in ATTR-CM; acoramidis has received regulatory approval in several countries; finding supports clinical monitoring of loop diuretic changes as an early warning system in ATTR-CM patients.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.